Market Research Logo

CSL Limited - Product Pipeline Review - 2015

CSL Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘CSL Limited - Product Pipeline Review - 2015’, provides an overview of the CSL Limited’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CSL Limited’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CSL Limited including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CSL Limited’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CSL Limited’s pipeline products
Reasons to buy
  • Evaluate CSL Limited’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CSL Limited in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CSL Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CSL Limited and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CSL Limited
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CSL Limited and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


CSL Limited Snapshot
CSL Limited Overview
Key Information
Key Facts
CSL Limited - Research and Development Overview
Key Therapeutic Areas
CSL Limited - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
CSL Limited - Pipeline Products Glance
CSL Limited - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Filing rejected/Withdrawn Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
CSL Limited - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
CSL Limited - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
CSL Limited - Drug Profiles
albutrepenonacog alfa
Product Description
Mechanism of Action
R&D Progress
antihemophilic factor (recombinant)
Product Description
Mechanism of Action
R&D Progress
haemophilus influenzae [serotype B] vaccine
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine
Product Description
Mechanism of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine
Product Description
Mechanism of Action
R&D Progress
seasonal influenza (quadrivalent) vaccine
Product Description
Mechanism of Action
R&D Progress
(prothrombin + coagulation factor VII human + coagulation factor IX human + coagulation factor X human + protein C + protein S human)
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human)
Product Description
Mechanism of Action
R&D Progress
CSL-689
Product Description
Mechanism of Action
R&D Progress
CSL-112
Product Description
Mechanism of Action
R&D Progress
CSL-311
Product Description
Mechanism of Action
R&D Progress
factor XIII (human)
Product Description
Mechanism of Action
R&D Progress
influenza [strain H5N1] vaccine
Product Description
Mechanism of Action
R&D Progress
seasonal influenza (trivalent) vaccine
Product Description
Mechanism of Action
R&D Progress
influenza [strain A/H3N2] (monovalent) vaccine
Product Description
Mechanism of Action
R&D Progress
influenza [strain H7N9] (monovalent) vaccine
Product Description
Mechanism of Action
R&D Progress
2H-10
Product Description
Mechanism of Action
R&D Progress
CSL-312
Product Description
Mechanism of Action
R&D Progress
CSL-324
Product Description
Mechanism of Action
R&D Progress
CSL-346
Product Description
Mechanism of Action
R&D Progress
CSL-650
Product Description
Mechanism of Action
R&D Progress
Drug for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Hematological Disorders
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
PODCRC-OHS
Product Description
Mechanism of Action
R&D Progress
Proteins for Undisclosed Indication
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein for Hemophilia
Product Description
Mechanism of Action
R&D Progress
CSL Limited - Pipeline Analysis
CSL Limited - Pipeline Products by Target
CSL Limited - Pipeline Products by Route of Administration
CSL Limited - Pipeline Products by Molecule Type
CSL Limited - Pipeline Products by Mechanism of Action
CSL Limited - Recent Pipeline Updates
CSL Limited - Dormant Projects
CSL Limited - Company Statement
CSL Limited - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
CSL Limited, Key Information
CSL Limited, Key Facts
CSL Limited - Pipeline by Indication, 2015
CSL Limited - Pipeline by Stage of Development, 2015
CSL Limited - Monotherapy Products in Pipeline, 2015
CSL Limited - Combination Treatment Modalities in Pipeline, 2015
CSL Limited - Partnered Products in Pipeline, 2015
CSL Limited - Partnered Products/ Combination Treatment Modalities, 2015
CSL Limited - Out-Licensed Products in Pipeline, 2015
CSL Limited - Out-Licensed Products/ Combination Treatment Modalities, 2015
CSL Limited - Pre-Registration, 2015
CSL Limited - Filing rejected/Withdrawn, 2015
CSL Limited - Phase III, 2015
CSL Limited - Phase II, 2015
CSL Limited - Phase I, 2015
CSL Limited - Preclinical, 2015
CSL Limited - Discovery, 2015
CSL Limited - Pipeline by Target, 2015
CSL Limited - Pipeline by Route of Administration, 2015
CSL Limited - Pipeline by Molecule Type, 2015
CSL Limited - Pipeline Products by Mechanism of Action, 2015
CSL Limited - Recent Pipeline Updates, 2015
CSL Limited - Dormant Developmental Projects,2015
CSL Limited, Other Locations
CSL Limited, Subsidiaries
List of Figures
CSL Limited - Pipeline by Top 10 Indication, 2015
CSL Limited - Pipeline by Stage of Development, 2015
CSL Limited - Monotherapy Products in Pipeline, 2015
CSL Limited - Combination Treatment Modalities in Pipeline, 2015
CSL Limited - Partnered Products in Pipeline, 2015
CSL Limited - Out-Licensed Products in Pipeline, 2015
CSL Limited - Pipeline by Top 10 Target, 2015
CSL Limited - Pipeline by Top 10 Route of Administration, 2015
CSL Limited - Pipeline by Top 10 Molecule Type, 2015
CSL Limited - Pipeline Products by Top 10 Mechanism of Action, 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report